Discover the detailed record of transactions filed by ZANTE GREG, Chief Financial Officer. Officer active across 1 companies, notably Viking Therapeutics, Inc.. Cumulatively, 4 filings have been published. The latest transaction was filed on 3 January 2022 (Retenue fiscale). Regulator: SEC (Form 4). The full history is accessible without signup.
4 of 4 declarations
Greg Zante is the Chief Financial Officer of Viking Therapeutics, Inc. In this role, he oversees the company's financial operations, including financial planning and reporting. With a strong background in finance, he plays a key role in managing financial resources and regulatory compliance. His expertise is essential in ensuring the financial health of Viking Therapeutics and supporting its mission of innovation.